This Article Figures Only Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Smart, S. C. Articles by Sagar, K. B. Search for Related Content PubMed PubMed Citation Articles by Smart, S. C. Articles by Sagar, K. B.

CLINICAL STUDIES

Dobutamine-atropine stress echocardiography for risk stratification in patients with chronic left ventricular dysfunction

^a Medical College of Wisconsin, Division of Cardiovascular Medicine, Milwaukee, Wisconsin, USA

Manuscript received December 19, 1997; revised manuscript received August 27, 1998, accepted October 2, 1998.

Reprint requests and correspondence: Dr. Steven C. Smart, Medical College of Wisconsin, Division of Cardiovascular Medicine, 9200 W. Wisconsin Ave. Milwaukee, Wisconsin
ssmart{at}post.its.mcw.edu

Objective

To assess the prognostic value of sustained improvement, scar and inducible ischemia with or without viability in patients with chronic left ventricular dysfunction (LVD).

Background

Dobutamine-atropine stress echocardiography (DASE) accurately detects scar, reversible dysfunction and the extent of coronary artery disease in LVD.

Methods

Three hundred fifty consecutive patients (age 62 ± 13 years, mean ± SD, 215 men/135 women) with moderate to severe LVD (LVEF < 40%, mean 30 ± 8%) underwent DASE and were followed for 18 months. Dobutamine-atropine stress echocardiographic findings were classified according to sustained improvement in all vascular territories, scar, inducible ischemia (worsening wall motion at peak dose only or biphasic responses) and their extent.

Results

Sustained improvement occurred in 83 patients (24%), scar alone in 99 (28%) and inducible ischemia in 168 (48%, with biphasic responses in 104). Ischemia was induced in all vascular territories in 26 patients. Patients with sustained improvement or scar alone were treated medically, whereas 46% (78/168) with inducible ischemia were revascularized (coronary bypass surgery, n = 67 or angioplasty, n = 11). There were 76 hard events including cardiac death in 59, nonfatal myocardial infarction in 11, and resuscitated sudden death in 6. Hard events were rare in sustained improvement (5%, 4/83), uncommon in scar (13%, 13/99) and common (p < 0.01) in medically treated patients with inducible ischemia (59%, 53/90). Cardiac deaths were especially common (p < 0.01) in patients with biphasic responses (55%, 28/51). Inducible ischemia independently predicted hard events (² = 75.35, p < 0.001) along with reduced LVEF at peak dose (² = 8.38, p = 0.004). Hard cardiac events were uncommon (8%, 6/78, p < 0.001) in patients with inducible ischemia who underwent early revascularization.

Conclusions

Inducible ischemia during DASE was the major determinant of outcome in LVD and independent of clinical data and left ventricular function. Improved wall thickening alone and scar alone predicted good outcome. Survival of patients with inducible ischemia was better after revascularization.

Abbreviations and Acronyms   BPM = beats per minute   CAD = coronary artery disease   DASE = dobutamine-atropine stress echocardiography   LVD = chronic left ventricular dysfunction   LVEF = left ventricular ejection fraction   PET = positron emission tomography

This article has been cited by other articles:

				V Rizzello, D Poldermans, A F L Schinkel, E Biagini, E Boersma, A Elhendy, F B Sozzi, A Maat, F Crea, J R T C Roelandt, et al. Long term prognostic value of myocardial viability and ischaemia during dobutamine stress echocardiography in patients with ischaemic cardiomyopathy undergoing coronary revascularisation Heart, February 1, 2006; 92(2): 239 - 244. [Abstract] [Full Text] [PDF]

				S. Sawada, A. Bapat, D. Vaz, J. Weksler, N. Fineberg, A. Greene, I. Gradus-Pizlo, and H. Feigenbaum Incremental value of myocardial viability for prediction of Long-Term prognosis in surgically revascularized patients with left ventricular dysfunction J. Am. Coll. Cardiol., December 17, 2003; 42(12): 2099 - 2105. [Abstract] [Full Text] [PDF]

				A D'Andrea, S Severino, P Caso, L De Simone, B Liccardo, A Forni, M Pascotto, G Di Salvo, M Scherillo, N Mininni, et al. Prognostic value of pharmacological stress echocardiography in diabetic patients Eur J Echocardiogr, September 1, 2003; 4(3): 202 - 208. [Abstract] [Full Text] [PDF]

				J. Meluzin, J. Cerny, L. Spinarova, J. Toman, L. Groch, F. Stetka, M. Frelich, P. Hude, J. Krejci, L. Rambouskova, et al. Prognosis of patients with chronic coronary artery disease and severe left ventricular dysfunction. The importance of myocardial viability Eur J Heart Fail, January 1, 2003; 5(1): 85 - 93. [Abstract] [Full Text] [PDF]

				P. Jourdain, F. Funck, Y. Fulla, A. Hagege, M. Bellorini, N. Guillard, J. Loiret, B. Thebault, and M. Desnos Myocardial contractile reserve under low doses of dobutamine and improvement of left ventricular ejection fraction with treatment by carvedilol Eur J Heart Fail, June 1, 2002; 4(3): 269 - 276. [Abstract] [Full Text] [PDF]

				K. C. Allman, L. J. Shaw, R. Hachamovitch, and J. E. Udelson Myocardial viability testing and impact of revascularization on prognosis in patients with coronary artery disease and left ventricular dysfunction: a meta-analysis J. Am. Coll. Cardiol., April 3, 2002; 39(7): 1151 - 1158. [Abstract] [Full Text] [PDF]

				E. Tadamura, H. Iida, K. Matsumoto, M. Mamede, S. Kubo, H. Toyoda, T. Shiozaki, T. Mukai, Y. Magata, and J. Konishi Comparison of myocardial blood flow during dobutamine-atropine infusion with that after dipyridamole administration in normal men J. Am. Coll. Cardiol., January 1, 2001; 37(1): 130 - 136. [Abstract] [Full Text] [PDF]